Published in Nat Genet on April 26, 2012
Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med (2015) 4.77
Mosaic PPM1D mutations are associated with predisposition to breast and ovarian cancer. Nature (2012) 2.66
Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discov (2014) 1.80
Inherited Mutations in Women With Ovarian Carcinoma. JAMA Oncol (2016) 1.76
Meta-analysis identifies four new loci associated with testicular germ cell tumor. Nat Genet (2013) 1.74
Two decades after BRCA: setting paradigms in personalized cancer care and prevention. Science (2014) 1.74
Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb Perspect Biol (2015) 1.73
Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. J Natl Cancer Inst (2015) 1.70
HELQ promotes RAD51 paralogue-dependent repair to avert germ cell loss and tumorigenesis. Nature (2013) 1.57
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer (2015) 1.53
Clinical characteristics of ovarian cancer classified by BRCA1, BRCA2, and RAD51C status. Sci Rep (2014) 1.02
Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. J Clin Oncol (2015) 1.01
The onset of p53 loss of heterozygosity is differentially induced in various stem cell types and may involve the loss of either allele. Cell Death Differ (2014) 0.99
PARP inhibitors in ovarian cancer. Br J Cancer (2015) 0.97
Germline mutation in the RAD51B gene confers predisposition to breast cancer. BMC Cancer (2013) 0.95
Diseases associated with defective responses to DNA damage. Cold Spring Harb Perspect Biol (2012) 0.94
Hereditary breast and ovarian cancer: new genes in confined pathways. Nat Rev Cancer (2016) 0.94
Human DNA helicase HELQ participates in DNA interstrand crosslink tolerance with ATR and RAD51 paralogs. Nat Commun (2013) 0.89
Counselling framework for moderate-penetrance cancer-susceptibility mutations. Nat Rev Clin Oncol (2016) 0.87
Ovarian cancer: in search of better marker systems based on DNA repair defects. Int J Mol Sci (2013) 0.87
Germline multi-gene hereditary cancer panel testing in an unselected endometrial cancer cohort. Mod Pathol (2016) 0.87
Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer. J Clin Oncol (2016) 0.85
Regulators of homologous recombination repair as novel targets for cancer treatment. Front Genet (2015) 0.81
DNA crosslinking damage and cancer - a tale of friend and foe. Transl Cancer Res (2013) 0.81
RAD51C deletion screening identifies a recurrent gross deletion in breast cancer and ovarian cancer families. Breast Cancer Res (2013) 0.78
RAD51C--a new human cancer susceptibility gene for sporadic squamous cell carcinoma of the head and neck (HNSCC). Oral Oncol (2013) 0.78
Screening of Finnish RAD51C founder mutations in prostate and colorectal cancer patients. BMC Cancer (2012) 0.78
UK BRCA mutation testing in patients with ovarian cancer. Br J Cancer (2015) 0.78
Genomic Biomarkers for Breast Cancer Risk. Adv Exp Med Biol (2016) 0.77
Targeted massively parallel sequencing of a panel of putative breast cancer susceptibility genes in a large cohort of multiple-case breast and ovarian cancer families. J Med Genet (2015) 0.77
Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic. PLoS One (2015) 0.76
RAD51B in Familial Breast Cancer. PLoS One (2016) 0.75
Identification, genetic testing, and management of hereditary melanoma. Cancer Metastasis Rev (2017) 0.75
RAD51, XRCC3, and XRCC2 mutation screening in Finnish breast cancer families. Springerplus (2015) 0.75
Recent Advances in Understanding, Diagnosing, and Treating Ovarian Cancer. F1000Res (2017) 0.75
Testing times. Nat Genet (2012) 0.75
Mechanism and disease association of E2-conjugating enzymes: lessons from UBE2T and UBE2L3. Biochem J (2016) 0.75
Detecting splicing patterns in genes involved in hereditary breast and ovarian cancer. Eur J Hum Genet (2017) 0.75
Recent advances in targeting DNA repair pathways for the treatment of ovarian cancer and their clinical relevance. Int J Clin Oncol (2017) 0.75
BRCA mutation in ovarian cancer: testing, implications and treatment considerations. Ther Adv Med Oncol (2017) 0.75
Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. Oncotarget (2017) 0.75
A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer. Nat Genet (2017) 0.75
Characterisation of the novel deleterious RAD51C p.Arg312Trp variant and prioritisation criteria for functional analysis of RAD51C missense changes. Br J Cancer (2017) 0.75
Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet (2006) 7.72
Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet (2010) 5.48
Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet (2011) 3.25
RAD51C is a susceptibility gene for ovarian cancer. Hum Mol Genet (2011) 1.80
ATM and breast cancer susceptibility. Oncogene (2006) 1.68
BRIP1, PALB2, and RAD51C mutation analysis reveals their relative importance as genetic susceptibility factors for breast cancer. Breast Cancer Res Treat (2011) 1.46
Analysis of RAD51C germline mutations in high-risk breast and ovarian cancer families and ovarian cancer patients. Hum Mutat (2011) 1.38
Further evidence for the contribution of the RAD51C gene in hereditary breast and ovarian cancer susceptibility. Breast Cancer Res Treat (2011) 1.24
Fanconi anemia and breast cancer susceptibility meet again. Nat Genet (2010) 1.22
RAD51C germline mutations in breast and ovarian cancer patients. Breast Cancer Res (2010) 1.20
Screening RAD51C nucleotide alterations in patients with a family history of breast and ovarian cancer. Breast Cancer Res Treat (2010) 1.17
RAD51C germline mutations in breast and ovarian cancer cases from high-risk families. PLoS One (2011) 1.12
A HRM-based screening method detects RAD51C germ-line deleterious mutations in Spanish breast and ovarian cancer families. Breast Cancer Res Treat (2011) 1.08
RAD51C germline mutations in Chinese women with familial breast cancer. Breast Cancer Res Treat (2011) 0.95
Mutation screening of RAD51C in male breast cancer patients. Breast Cancer Res (2011) 0.89
A census of human cancer genes. Nat Rev Cancer (2004) 36.20
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet (2007) 12.62
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet (2002) 9.71
Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med (2008) 9.64
PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. Nat Genet (2006) 9.17
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. Nat Genet (2006) 7.72
Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet (2010) 7.62
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol (2006) 7.33
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet (2011) 6.77
ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nat Genet (2006) 6.67
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet (2006) 5.12
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med (2015) 4.77
Constitutional aneuploidy and cancer predisposition caused by biallelic mutations in BUB1B. Nat Genet (2004) 4.58
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
The emerging landscape of breast cancer susceptibility. Nat Genet (2008) 4.27
Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. J Med Genet (2006) 4.23
Assessing women at high risk of breast cancer: a review of risk assessment models. J Natl Cancer Inst (2010) 3.94
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Chromosome 6p22 locus associated with clinically aggressive neuroblastoma. N Engl J Med (2008) 3.80
Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med (2008) 3.76
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet (2010) 3.57
Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol (2008) 3.54
MRI breast screening in high-risk women: cancer detection and survival analysis. Breast Cancer Res Treat (2014) 3.46
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42
Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Am J Hum Genet (2008) 3.41
Genetic predisposition to breast cancer: past, present, and future. Annu Rev Genomics Hum Genet (2008) 3.40
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Bayesian refinement of association signals for 14 loci in 3 common diseases. Nat Genet (2012) 3.31
Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nat Genet (2011) 3.25
Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet (2003) 3.24
Genome-wide association analysis identifies three new breast cancer susceptibility loci. Nat Genet (2012) 3.20
Human chromosome 7: DNA sequence and biology. Science (2003) 3.02
Variants near DMRT1, TERT and ATF7IP are associated with testicular germ cell cancer. Nat Genet (2010) 2.99